Literature DB >> 35852368

The Antifungal and Anti-Pneumocystis Activities of the Novel Compound A3IS (Mycosinate).

Nathan P Wiederhold1, Thomas F Patterson2,3, Sandra Rebholz4,5, Connell W C Boal6, Monika Ehrensberger6, Ryan Boyle6, Melanie T Cushion4,5.   

Abstract

A3IS (Mycosinate) is a synthetic product which only contains ingredients found naturally within honey. A3IS is a broad-spectrum antimicrobial product which produces a sustained release of hydrogen peroxide at low but therapeutic levels. The product elicits this release through an enzymatic reaction between glucose oxidase and the substrate glucose once the product is hydrated. As medical uses for different honeys are being re-evaluated, the purpose of this study was to evaluate the in vitro effects of A3IS against a comprehensive panel of human pathogens, including Pneumocystis species, providing a unique assessment against a panel of eukaryotic pathogens. Without exception, A3IS exhibited significant efficacy at 50% and 100% inhibitory concentrations against a broad spectrum of human pathogens including yeasts, molds (both hyaline and dematiaceous), and dimorphic fungi. Notably, A3IS was effective against fungal strains with a high level of resistance to fluconazole or voriconazole. The 50% inhibitory concentrations for Pneumocystis carinii and P. murina (surrogates for P. jirovecii) were considered "Marked" and "Moderate" on an established rank scale, and would be considered for in vivo studies, based on an established in vitro-in vivo pipeline. These results indicate that A3IS is a novel anti-fungal agent against an extensive range of human fungal pathogens.

Entities:  

Keywords:  antifungal susceptibility testing

Mesh:

Substances:

Year:  2022        PMID: 35852368      PMCID: PMC9380569          DOI: 10.1128/aac.00521-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  16 in total

1.  Antibiofilm efficacy of honey and bee-derived defensin-1 on multispecies wound biofilm.

Authors:  Martin Sojka; Ivana Valachova; Marcela Bucekova; Juraj Majtan
Journal:  J Med Microbiol       Date:  2016-02-08       Impact factor: 2.472

2.  Pneumocystis jirovecii: a review with a focus on prevention and treatment.

Authors:  R Benson Weyant; Dima Kabbani; Karen Doucette; Cecilia Lau; Carlos Cervera
Journal:  Expert Opin Pharmacother       Date:  2021-04-19       Impact factor: 3.889

Review 3.  Natural products against renin-angiotensin system for antifibrosis therapy.

Authors:  Tian Yang; Yuan-Yuan Chen; Jing-Ru Liu; Hui Zhao; Nosratola D Vaziri; Yan Guo; Ying-Yong Zhao
Journal:  Eur J Med Chem       Date:  2019-06-29       Impact factor: 6.514

4.  Antifungal effect of lavender honey against Candida albicans , Candida krusei and Cryptococcus neoformans.

Authors:  Maria Leticia Estevinho; Sílvia Esteves Afonso; Xesús Feás
Journal:  J Food Sci Technol       Date:  2011-02-11       Impact factor: 2.701

5.  Characterizing the Mechanism of Action of an Ancient Antimicrobial, Manuka Honey, against Pseudomonas aeruginosa Using Modern Transcriptomics.

Authors:  Daniel Bouzo; Nural N Cokcetin; Liping Li; Giulia Ballerin; Amy L Bottomley; James Lazenby; Cynthia B Whitchurch; Ian T Paulsen; Karl A Hassan; Elizabeth J Harry
Journal:  mSystems       Date:  2020-06-30       Impact factor: 6.496

Review 6.  Preclinical drug discovery for new anti-pneumocystis compounds.

Authors:  Melanie T Cushion; Peter D Walzer
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

7.  Agastache honey has superior antifungal activity in comparison with important commercial honeys.

Authors:  Sushil Anand; Margaret Deighton; George Livanos; Edwin Chi Kyong Pang; Nitin Mantri
Journal:  Sci Rep       Date:  2019-12-03       Impact factor: 4.379

Review 8.  Advances in Antifungal Drug Development: An Up-To-Date Mini Review.

Authors:  Ghada Bouz; Martin Doležal
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-16

Review 9.  Advances in anti-fungal therapies.

Authors:  Grant Waterer
Journal:  Mycopathologia       Date:  2021-07-15       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.